NR2B- and NR2D-containing synaptic NMDA receptors in developing rat substantia nigra pars compacta dopaminergic neurones

Journal of Physiology

Volumn 586, Issue 3, 2008, Pages 739-750

  Brothwell, S L C ^a   Barber, J L ^a   Monaghan, D T ^b   Jane, D E ^c   Gibb, A J ^d   Jones, S ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; IFENPRODIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2D; RECEPTOR SUBUNIT; UNCLASSIFIED DRUG; ZINC; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SYNAPSE RECEPTOR; ZINC ION;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; ELECTROPHYSIOLOGY; IC 50; NERVE CELL PLASTICITY; NONHUMAN; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SUBSTANTIA NIGRA; SYNAPTIC TRANSMISSION; ANIMAL EXPERIMENT; BRAIN DEVELOPMENT; EXCITATORY POSTSYNAPTIC POTENTIAL; IC50; PERINATAL PERIOD; SUBSTANTIA NIGRA PARS COMPACTA; SYNAPTIC INHIBITION;

ANIMALS; ANIMALS, NEWBORN; DOPAMINE; NEURONS; PATCH-CLAMP TECHNIQUES; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; SUBSTANTIA NIGRA; SYNAPSES;

EID: 38849204753     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2007.144618     Document Type: Article

References (67)

1. Albers DS, Weiss SW, Ladarola MJ & Standaert DG (1999). Immunohistochemical localization of N-methyl-D-aspartate and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor subunits in the substantia nigra pars compacta of the rat. Neuroscience 89, 209-220.
2. Auberson YP, Allgeier H, Bischoff S, Lingenhoehl K, Moretti R & Schmutz M (2002). 5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition. Bioorg Med Chem Lett 12, 1099-1102.
3. Berberich S, Punnakkal P, Jensen V, Pawlak V, Seeburg PH, Hvalby O & Kohr G (2005). Lack of NMDA receptor subtype selectivity for hippocampal long-term potentiation. J Neurosci 25, 6907-6910.
4. Blanchet PJ, Konitsiotis S, Whittemore ER, Zhou ZL, Woodward RM & Chase TN (1999). Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J Pharmacol Exp Ther 290, 1034-1040.
5. Blandini F, Nappi G, Tassorelli C & Martignoni E (2000). Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol 62, 63-88.
6. Bonci A & Malenka RC (1999). Properties and plasticity of excitatory synapses on dopaminergic and GABAergic cells in the ventral tegmental area. J Neurosci 19, 3723-3730.
7. Borgland SL, Taha SA, Sarti F, Fields HL & Bonci A (2006). Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. Neuron 49, 589-601.
8. Brickley SG, Misra C, Mok MH, Mishina M & Cull-Candy SG (2003). NR2B and NR2D subunits coassemble in cerebellar Golgi cells to form a distinct NMDA receptor subtype restricted to extrasynaptic sites. J Neurosci 23, 4958-4966.
9. Buller AL, Larson HC, Schneider BE, Beaton JA, Morrisett RA & Monaghan DT (1994). The molecular basis of NMDA receptor subtypes: native receptor diversity is predicted by subunit composition. J Neurosci 14, 5471-5484.
10. Buller AL & Monaghan DT (1997). Pharmacological heterogeneity of NMDA receptors: Characterization of NR1a/NR2D heteromers expressed in Xenopus oocytes. Eur J Pharmacol 320, 87-94.
11. Chazot PL, Lawrence S & Thompson CL (2002). Studies on the subtype selectivity of CP-101,606: Evidence for two classes of NR2B-selective NMDA receptor antagonists. Neuropharmacology 42, 319-324.
12. Chazot PL & Stephenson FA (1997). Molecular dissection of native mammalian forebrain NMDA receptors containing the NR1 C2 exon: Direct demonstration of NMDA receptors comprising NR1, NR2A, and NR2B subunits within the same complex. J Neurochem 69, 2138-2144.
13. Cheffings CM & Colquhoun D (2000). Single channel analysis of a novel NMDA channel from Xenopus oocytes expressing recombinant NR1a, NR2A and NR2D subunits. J Physiol 526, 481-491.
14. Cull-Candy S, Brickley S & Farrant M (2001). NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol 11, 327-335.
15. Cull-Candy SG & Leszkiewicz DN (2004). Role of distinct NMDA receptor subtypes at central synapses. Sci STKE, re16.
16. Doble A (1999). The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther 81, 163-221.
17. Dunah AW, Luo J, Wang YH, Yasuda RP & Wolfe BB (1998). Subunit composition of N-methyl-D-aspartate receptors in the central nervous system that contain the NR2D subunit. Mol Pharmacol 53, 429-437.
18. Dunah AW, Yasuda RP, Wang YH, Luo J, Davila-Garcia M, Gbadegesin M, Vicini S & Wolfe BB (1996). Regional and ontogenic expression of the NMDA receptor subunit NR2D protein in rat brain using a subunit-specific antibody. J Neurochem 67, 2335-2345.
19. Feng B, Tse HW, Skifter DA, Morley R, Jane DE & Monaghan DT (2004). Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2,3-dicarboxylic acid. Br J Pharmacol 141, 508-516.
20. Flint AC, Maisch US, Weishaupt JH, Kriegstein AR & Monyer H (1997). NR2A subunit expression shortens NMDA receptor synaptic currents in developing neocortex. J Neurosci 17, 2469-2476.
21. Frizelle PA, Chen PE & Wyllie DJ (2006). Equilibrium constants for (R) -[(S)
22. Hallett PJ & Standaert DG (2004). Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol Ther 102, 155-174.
23. Hatton CJ & Paoletti P (2005). Modulation of triheteromeric NMDA receptors by N-terminal domain ligands. Neuron 46, 261-274.
24. Hestrin S (1992). Developmental regulation of NMDA receptor-mediated synaptic currents at a central synapse. Nature 357, 686-689.
25. Hrabetova S, Serrano P, Blace N, Tse HW, Skifter DA, Jane DE, Monaghan DT & Sacktor TC (2000). Distinct NMDA receptor subpopulations contribute to long-term potentiation and long-term depression induction. J Neurosci 20, RC81.
26. Johnson SW & North RA (1992). Two types of neurone in the rat ventral tegmental area and their synaptic inputs. J Physiol 450, 455-468.
27. Johnson SW, Seutin V & North RA (1992). Burst firing in dopamine neurons induced by N-methyl-D-aspartate: Role of electrogenic sodium pump. Science 258, 665-667.
28. Johnson SW & Wu YN (2004). Multiple mechanisms underlie burst firing in rat midbrain dopamine neurons in vitro. Brain Res 1019, 293-296.
29. Jones S & Gibb AJ (2005). Functional NR2B- and NR2D-containing NMDA receptor channels in rat substantia nigra dopaminergic neurones. J Physiol 569, 209-221.
30. Katz LC & Shatz CJ (1996). Synaptic activity and the construction of cortical circuits. Science 274, 1133-1138.
31. 2+ block in NMDA receptor channels. J Neurosci 16, 3549-3558.
32. Liu L, Wong TP, Pozza MF, Lingenhoehl K, Wang Y, Sheng M, Auberson YP & Wang YT (2004 a). Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science 304, 1021-1024.
33. Liu XB, Murray KD & Jones EG (2004 b). Switching of NMDA receptor 2A and 2B subunits at thalamic and cortical synapses during early postnatal development. J Neurosci 24, 8885-8895.
34. Lozovaya NA, Grebenyuk SE, Tsintsadze T, Feng B, Monaghan DT & Krishtal OA (2004). Extrasynaptic NR2B and NR2D subunits of NMDA receptors shape 'superslow'afterburst EPSC in rat hippocampus. J Physiol 558, 451-463.
35. Margolis EB, Lock H, Hjelmstad GO & Fields HL (2006). The ventral tegmental area revisited: Is there an electrophysiological marker for dopaminergic neurons? J Physiol 577, 907-924.
36. Massey PV, Johnson BE, Moult PR, Auberson YP, Brown MW, Molnar E, Collingridge GL & Bashir ZI (2004). Differential roles of NR2A and NR2B-containing NMDA receptors in cortical long-term potentiation and long-term depression. J Neurosci 24, 7821-7828.
37. Mereu G, Costa E, Armstrong DM & Vicini S (1991). Glutamate receptor subtypes mediate excitatory synaptic currents of dopamine neurons in midbrain slices. J Neurosci 11, 1359-1366.
38. Monyer H, Burnashev N, Laurie DJ, Sakmann B & Seeburg PH (1994). Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12, 529-540.
39. Morley RM, Tse HW, Feng B, Miller JC, Monaghan DT & Jane DE (2005). Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem 48, 2627-2637.
40. Mott DD, Doherty JJ, Zhang S, Washburn MS, Fendley MJ, Lyuboslavsky P, Traynelis SF & Dingledine R (1998). Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. Nat Neurosci 1, 659-667.
41. Nase G, Weishaupt J, Stern P, Singer W & Monyer H (1999). Genetic and epigenetic regulation of NMDA receptor expression in the rat visual cortex. Eur J Neurosci 11, 4320-4326.
42. Nash JE, Fox SH, Henry B, Hill MP, Peggs D, McGuire S, Maneuf Y, Hille C, Brotchie JM & Crossman AR (2000). Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol 165, 136-142.
43. Nash JE, Hill MP & Brotchie JM (1999). Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat. Exp Neurol 155, 42-48.
44. 2+ signals evoked by coincident EPSPs and backpropagating action potentials in spiny stellate cells of layer 4 in the juvenile rat somatosensory barrel cortex. J Neurosci 24, 1689-1699.
45. Neyton J & Paoletti P (2006). Relating NMDA receptor function to receptor subunit composition: Limitations of the pharmacological approach. J Neurosci 26, 1331-1333.
46. Okabe S, Collin C, Auerbach JM, Meiri N, Bengzon J, Kennedy MB, Segal M & McKay RDG (1998). Hippocampal synaptic plasticity in mice overexpressing an embryonic subunit of the NMDA receptor. J Neurosci 18, 4177-4188.
47. Paoletti P, Ascher P & Neyton J (1997). High-affinity zinc inhibition of NMDA NR1-NR2A receptors. J Neurosci 17, 5711-5725.
48. Paoletti P & Neyton J (2007). NMDA receptor subunits: Function and pharmacology. Curr Opin Pharmacol 7, 39-47.
49. Prakash N & Wurst W (2006). Development of dopaminergic neurons in the mammalian brain. Cell Mol Life Sci 63, 187-206.
50. 2+ block of NR1/2D NMDA receptors. J Neurosci 26, 10899-10910.
51. Rachline J, Perin-Dureau F, Le Goff A, Neyton J & Paoletti P (2005). The micromolar zinc-binding domain on the NMDA receptor subunit NR2B. J Neurosci 25, 308-317.
52. Sheng M, Cummings J, Roldan LA, Jan YN & Jan LY (1994). Changing subunit composition of heteromeric NMDA receptors during development of rat cortex. Nature 368, 144-147.
53. Steece-Collier K, Chambers LK, Jaw-Tsai SS, Menniti FS & Greenamyre JT (2000). Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-D-aspartate receptors. Exp Neurol 163, 239-243.
54. Stern P, Behe P, Schoepfer R & Colquhoun D (1992). Single-channel conductances of NMDA receptors expressed from cloned cDNAs: Comparison with native receptors. Proc Biol Sci 250, 271-277.
55. Stocca G & Vicini S (1998). Increased contribution of NR2A subunit to synaptic NMDA receptors in developing rat cortical neurons. J Physiol 507, 13-24.
56. Tovar KR & Westbrook GL (1999). The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses in vitro. J Neurosci 19, 4180-4188.
57. Vicini S & Rumbaugh G (2000). A slow NMDA channel: In search of a role. J Physiol 525, 283.
58. Vicini S, Wang JF, Li JH, Zhu WJ, Wang YH, Luo JH, Wolfe BB & Grayson DR (1998). Functional and pharmacological differences between recombinant N-methyl-D-aspartate receptors. J Neurophysiol 79, 555-566.
59. Wenzel A, Fritschy JM, Mohler H & Benke D (1997). NMDA receptor heterogeneity during postnatal development of the rat brain: differential expression of the NR2A, NR2B, and NR2C subunit proteins. J Neurochem 68, 469-478.
60. Williams K (1993). Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: Selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol 44, 851-859.
61. Williams K (1995). Pharmacological properties of recombinant N-methyl-D-aspartate (NMDA) receptors containing the epsilon 4 (NR2D) subunit. Neurosci Lett 184, 181-184.
62. Williams K (2001). Ifenprodil, a novel NMDA receptor antagonist: Site and mechanism of action. Curr Drug Targets 2, 285-298.
63. Williams K, Russell SL, Shen YM & Molinoff PB (1993). Developmental switch in the expression of NMDA receptors occurs in vivo and in vitro. Neuron 10, 267-278.
64. Wu YN & Johnson SW (1996). Pharmacological characterization of inward current evoked by N-methyl-D-aspartate in dopamine neurons in the rat brain slice. J Pharmacol Exp Ther 279, 457-463.
65. Wyllie DJ, Behe P & Colquhoun D (1998). Single-channel activations and concentration jumps: Comparison of recombinant NR1a/NR2A and NR1a/ NR2D NMDA receptors. J Physiol 510, 1-18.
66. Wyllie DJ, Behe P, Nassar M, Schoepfer R & Colquhoun D (1996). Single-channel currents from recombinant NMDA NR1a/NR2D receptors expressed in Xenopus oocytes. Proc Biol Sci 263, 1079-1086.
67. Zhou M & Baudry M (2006). Developmental changes in NMDA neurotoxicity reflect developmental changes in subunit composition of NMDA receptors. J Neurosci 26, 2956-2963.